| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 12 analysts have shared their insights on Eastman Chemical (NYSE:EMN), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 1 | 3 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $110.42, a high estimate of $128.00, and a low estimate of $100.00. This current average has increased by 12.77% from the previous average price target of $97.92.
The perception of Eastman Chemical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Cunningham | Citigroup | Lowers | Buy | $111.00 | $114.00 |
| Joshua Spector | UBS | Raises | Buy | $128.00 | $106.00 |
| Michael Leithead | Barclays | Raises | Equal-Weight | $103.00 | $85.00 |
| Arun Viswanathan | RBC Capital | Raises | Sector Perform | $104.00 | $100.00 |
| Charles Neivert | Piper Sandler | Raises | Neutral | $105.00 | $90.00 |
| Laurence Alexander | Jefferies | Raises | Buy | $125.00 | $102.00 |
| Steve Byrne | B of A Securities | Lowers | Buy | $112.00 | $113.00 |
| John Roberts | Mizuho | Raises | Neutral | $102.00 | $91.00 |
| Arun Viswanathan | RBC Capital | Raises | Sector Perform | $100.00 | $89.00 |
| Michael Sison | Wells Fargo | Raises | Equal-Weight | $100.00 | $89.00 |
| Patrick Cunningham | Citigroup | Raises | Buy | $114.00 | $95.00 |
| Aleksey Yefremov | Keybanc | Raises | Overweight | $121.00 | $101.00 |
To gain a panoramic view of Eastman Chemical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Eastman Chemical analyst ratings.
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Eastman Chemical's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -4.23%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Eastman Chemical's net margin is impressive, surpassing industry averages. With a net margin of 7.14%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.12%, the company showcases effective utilization of assets.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average at 0.92, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EMN
